Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas

NCT00004212 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00004212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Completed
Start date
September 30, 1999
Completion date
April 30, 2004
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors, lymphoma, unspecified childhood solid tumor, protocol specific